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Abstract
Mesenchymal stem cells (MSCs) from adult somatic tissues may differentiate in vitro and in vivo into multiple mesodermal tissues
including bone, cartilage, adipose tissue, tendon, ligament or even muscle. MSCs preferentially home to damaged tissues where they
exert their therapeutic potential. A striking feature of the MSCs is their low inherent immunogenicity as they induce little, if any, prolif-
eration of allogeneic lymphocytes and antigen-presenting cells. Instead, MSCs appear to be immunosuppressive in vitro. Their multi-
lineage differentiation potential coupled to their immuno-privileged properties is being exploited worldwide for both autologous and allo-
geneic cell replacement strategies. Here, we introduce the readers to the biology of MSCs and the mechanisms underlying immune 
tolerance. We then outline potential cell replacement strategies and clinical applications based on the MSCs immunological properties.
Ongoing clinical trials for graft-versus-host-disease, haematopoietic recovery after co-transplantation of MSCs along with haematopoi-
etic stem cells and tissue repair are discussed. Finally, we review the emerging area based on the use of MSCs as a target cell subset
for either spontaneous or induced neoplastic transformation and, for modelling non-haematological mesenchymal cancers such 
as sarcomas. 
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Introduction
Mesenchymal stem cells (MSCs) are multi-potent cells present in a
variety of tissues during development and therefore can be isolated
from several and perhaps most adult tissues, although bone mar-
row (BM) represents the source most often used. The prevailing
consensus is that MSCs have similar biological characteristics
regardless of origin, but differences are likely to be reported in the
near future. It is now well accepted that MSCs constitute a source of
progenitors of mesoderm-derived tissues such as bone, cartilage
and fat. These multi-potent MSCs can be isolated based on plastic-
adherence properties [1] and expanded in culture relatively easy.
Stem Cells Review Series
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The definition of MSC generated ex vivo is a composite of phe-
notypical, morphological and functional characteristics, which
clearly illustrate that these cells constitute a heterogeneous popu-
lation. Expanded MSCs homogenously express a number of non-
specific markers, including CD105, CD73, CD166, CD44, CD90,
CD271 and CD29, which are shared by cultured mature fibroblasts
from any tissue. The most common surface antigens expressed in
human MSCs from distinct sources including BM and adipose-tis-
sue as well as mature human fibroblasts are displayed in Table 1.
Important efforts are being undertaken by many groups in the field
to identify suitable and reliable markers distinguishing MSCs from
mature fibroblasts. Similar to haematopoietic stem cells, the
absence of a unique specific marker represents a challenge for
MSC isolation. MSCs can be isolated by flow cytometry or mag-
netic cell-sorters using fluorescence- or magnetic-labelled surface
antigens. MSC-specific monoclonal antibodies against CD105,
CD73, CD271 and CD90 are available directly conjugated to dis-
tinct fluorochromes for FACS-isolation or to microbeads for mag-
netic purification (www.miltenyi.com or www.stemcell.com).
Importantly, MSC isolation may require a positive selection cou-
pled to depletion steps. This is due to the complex immunopheno-
type defining MSCs, which are positive for CD73, CD105, CD146,
CD271 among other markers but lack expression of CD34, CD45,
CD14, HLA-DR, and CD19. Although most, if not all, such markers
are highly modulated in culture, other markers such as STRO-1
[2], SSEA-1/CD15 [3], SSEA-4 [4] or CD146 [5] have been pro-
posed to label an in vivo mesenchymal precursor, though it is not
clear yet whether they define a subset of MSCs or the ‘master’ very
immature MSC. In addition to the phenotype, their differentiation
capacity using clonal cultures of MSCs has provided much infor-
mation about the in vitro heterogeneity of this population. While
most of the cells within a given MSC population show a uni- or
bipotential capacity of differentiation, there are only a small 
number of cells exhibiting tripotential differentiation capacity
(osteogenesis, chondrogenesis and adipogenesis). These data
suggest a possible hierarchical model where the tripotent cells can
be considered as early mesenchymal progenitors within a hetero-
geneous cell culture that displays a sequential loss of lineage
potential [6, 7].
Successful haematopoietic stem cell (HSC)-based therapies
have been carried out for almost 50 years. Infusion of high num-
bers of HSCs is associated with a rapid haematopoietic recovery
and low probability of graft failure [8] although it may be linked to
an increased incidence of graft-versus-host-disease (GVHD) in an
allogeneic setting [9]. Therefore, it is likely that future cell-based
therapies will require a tight control of the cell dose to be trans-
planted in order to achieve a successful and safe outcome. In vitro
expanded cells can overcome several problems associated with
the ever-growing issue of insufficient stem cell availability. Unlike
HSCs, which are prone to differentiation in vitro and therefore dif-
ficult to maintain in their stem cell potential, MSCs can be induced
to proliferate extensively in vitro while maintaining their undiffer-
entiated multi-potent stage.
From a clinical standpoint, MSCs as any other cell therapy
products are considered drugs and thereby need to follow 
the same legal manufacturing requirements (i.e. Good
Manufacturing Practice, GMP) if they are to be used into the
clinic [10]. To date, most of the ongoing clinical trials using
MSCs are developed with autologous cells generated in GMP
facilities. Importantly, however, several studies have shown that
MSCs are not inherently immunogenic and therefore escape
from immune surveillance in vivo [11–13], opening up new
promising avenues for the use of MSCs not only for autologous-
but also for allogeneic-cell therapies. Despite being costly, the
establishment of a stem-cell bank of well-characterized and
‘ready-to-use’ allogeneic MSCs could be an interesting approach
towards facilitating the access of investigators and clinicians to
this valuable material. Nevertheless, MSCs have different control
points, which regulate their life span in vitro, probably resulting
in limited cell growth. Accordingly, there is great controversy as
Molecule Alternative name 
hMSCs
(bone 
marrow) 
hMSCs 
(fat tissue) 
Mature
fibroblasts
(skin) 
CD13 APN 
CD14 LPS-R 
CD15 Lewis Ag 
CD29 Integrin 1 
CD31 PECAM-1
CD34 Sialomucin 
CD44 H-CAM 
CD45 
Leucocyte
Common Antigen 
CD73 
Ecto 5´nucleoti-
dase 
CD80 B7–1 
CD86 B7–2 
CD90 Thy-1 
CD105 Endoglin 
CD117 c-KIT 
CD133 AC133 
CD144 Cadherin-5 
CD146 MUC-18 
CD164 MUC-24 
CD166 ALCAM 
MHC class I 
MHC class II 
Table 1 Common surface markers used to characterize human MSCs
 Positive  Negative
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to whether MSCs undergo in vitro senescence and/or genetic
instability [14–16]. It is worth mentioning that the use of MSCs
for clinical purposes will require the biosafety of these primary
cells to be carefully investigated through appropriate and sensi-
tive cellular, molecular and genetic tests. Long-term in vitro
culture, culture medium conditions, microbiology and virology
tests and phenotype should be controlled together with high-
resolution molecular analysis and tumourogenesis in vivo
assays [17, 18].
The recognition of the therapeutic potential of MSCs is likely
the most exciting advance in cell therapy following the widespread
use of HSC transplantation (HSCT). The potential clinical use of
MSCs in tissue repair mainly involves bone, cartilage and tendon.
As discussed below, proof-of-principle for MSC-based cell therapy
has already been established for bone, as MSCs are currently
being exploited to repair segmental bone defects of critical size in
animals [19], to restore healing of non-union long bone fractures
in humans (www.aastrom.com) or to treat bones of children with
osteogenesis imperfecta [20]. Whether MSCs can generate any
other tissue in vivo still remains to be elucidated. Due to their
immunomodulatory properties, in addition to their regenerative
potential, MSCs are currently being explored in other therapeutic
approaches outlined in the present review: (i) to improve
haematopoietic reconstitution after HSCT and (ii) to overcome
GVHD upon allogeneic transplantation [21, 22] (clinical applica-
tions summarized in Table 2). Research efforts aimed at identify-
ing factors and/or cell membrane molecules that control MSC fate
decision are necessary to be able to determine the real potential of
MSC in cell therapy. In this review, we discuss the biological prop-
erties of MSCs that render them as promising candidates for basic
and clinical applications in cell replacement, tissue engineering,
immune-modulation in an allogeneic HSCT setting and, as poten-
tial target cells to develop in vitro and in vivo disease models for
human mesenchymal cancers.
Mechanisms of immunological 
tolerance
Immunological tolerance is often defined by the failure of the
immune system to mount a response against a specific antigen
[23, 24]. Although this conventional definition is useful from an
experimental point of view, it is not always operational in clinical
situations because under some circumstances, the immune sys-
tem can recognize a specific antigen without mounting a clinically
significant response causing tissue injury or graft rejection. For
example, immune deviation towards a certain profile of cytokine
production can protect from a pathogenic response mediated by
an opposing profile of cytokine production, preventing an undesir-
able immune response [25]. In those latter situations, one may
talk as clinical tolerance. The mechanisms of immune tolerance
reviewed in this section are mostly mediating conventional toler-
ance but some may be at work also in clinical tolerance.
Immunological tolerance has been traditionally divided in cen-
tral tolerance or peripheral tolerance depending on whether the
operating mechanisms take place mostly on the primary lymphoid
organs or in the periphery, in secondary lymphoid organs or ‘tar-
get’ tissues. Three main mechanisms (not mutually exclusive) are
at work in the induction of central tolerance. One is clonal deletion.
This is based on negative selection through the induction of apop-
tosis of autoreactive clones during their development in the BM
(for B cells) or in the thymus (for T cells) [26]. Another mecha-
nism of central tolerance is the induction of a state of anergy,
defined by the inability of B-cell or T-cell clones to mount a full
response to a specific antigen upon rechallenge. The induction of
anergy for immature B cells has been linked to the ligation of 
B-cell antigen receptors (a membrane-bound immunoglobulin) by
soluble antigens or monovalent (non-cross-linking) antigens [27,
28]. For developing thymocytes, the molecular mechanism of
anergy induction is unclear but may be linked to signalling through
the antigen receptor (TCR) in a partial agonist mode [29–31]. A
third mechanism that may lead to a state of clinical tolerance and
is operational in the thymus is the development of antigen-spe-
cific, ‘natural’ regulatory T cells (Tregs) that have the capacity to
suppress the development of immune responses in the periphery
[32]. These cells are positively selected in the thymus and are
characterized by the expression of transcription factor FoxP3.
Most of these cells express CD4 and CD25 as well.
The induction of tolerance in the BM or the thymus is a highly
efficient process. However, it does not guarantee the elimination of
all the autoreactive clones of T or B lymphocytes. Additional
mechanisms to prevent autoreactivity are operational in the
periphery. The cellular and molecular basis of some of these
mechanisms is the same as the one for mechanisms of central tol-
erance. For example, deletion of potential autoreactive T-cell
clones can occur as a result of activation-induced cell death upon
encounter with parenchymal cells that express ligands for death
receptors (e.g. FasL for Fas) [33] or upon recirculation into the
thymus of activated T cells [34, 35] or by the activity of veto cells
that kill autoreactive cytotoxic T cells [36]. Anergy, particularly 
T-cell anergy, has also been linked to tolerance by peripheral
mechanisms, mostly secondary to situations in which T cells rec-
ognize antigen in the absence of ligands (e.g. B7 family of mole-
cules) for costimulatory receptors (e.g. CD28), TCR signalling in
partial agonist mode, or after engagement of CTLA [37–41].
Administration of progenitors or immature dendritic cells may
contribute to the development of peripheral tolerance in part
through this mechanism [42]. At the biochemical level, the induc-
tion of T-cell anergy correlates with impairment of early TCR-
dependent signalling along the ras-dependent signalling [43, 44].
Of increasing importance is the key role that Tregs play in the
down-regulation of immune responses, and that may be critical
for the maintenance of a state of clinical tolerance to allografts. In
addition to thymic generation, Tregs can be induced in the periph-
ery from CD4 CD25 T cells, these Tregs being known as adap-
tive Tregs. These cells are heterogeneous in phenotype, with reg-
ulatory activity having been assigned to CD4CD8 T cells and 
T cells producing high amounts of TGF- and IL-10 (Tr1) [45–47].
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The specific mechanism of down-regulation immune responses
by Tregs remains unclear. For some of these subsets, cell-to-cell
contact is required; however, under some conditions, regulatory
activity may be secondary to the production of cytokines as IL-10
or TGF-.
In recent years, there has been a re-emerging interest in the
role that chimerism either macrochimerism or microchimerism
may play in the generation of an immune tolerant state. In solid
organ transplant recipients, such a state has likely emerged as a
result of expansion of ‘passenger’ leukocytes of donor origin in the
recipient [48]. The mechanisms of tolerance induction in
chimerism may operate centrally in the thymus or BM, and in the
periphery. Recent analysis of transplant recipients with long-term
functional grafts and that have stopped immunosuppressive ther-
apy have been useful to provide an emerging framework for
chimerism. Under most conditions, these involve the administra-
tion of limited rounds of treatment with immunosuppressive
drugs, including a pre-transplant period, to allow the cross-toler-
ization of both immune systems. The mechanism that are opera-
tional under these circumstances are mostly deletional mecha-
nisms, and stress the importance of dose, timing and targets of
immunosuppressive therapies as variables for future optimization
of tolerogenic protocols.
In the context of the mechanisms outlined above, administra-
tion of MSCs and HSCs stands as an attractive therapeutic candi-
date for the induction of immunological tolerance. It is of interest
to note that, historically, the tolerogenic capacity of HSCs may
have been operational in situations in which blood transfusions,
and donor-specific blood transfusions in particular for living
related kidney recipients, have been used [49, 50]. This strategy
had a beneficial effect on graft survival (when not inducing sensi-
tization of the recipient). The advances in our understanding of the
tolerogenic mechanism lead us to consider several possibilities
for the immunomodulatory and tolerogenic properties of MSCs
Table 2 Clinical applications based on the use of MSCs: advantages and pitfalls
Potential clinical application Advantages Disadvantages/Pitfalls 
Engineering cartilage, bone, muscle, fat and
tendon for cell replacement strategies 
-Existence of MSCs in multiple tissues -
Relatively reproducible differentiation proto-
cols-Low immunogeneicity -Opposite to HSCs,
MSCs proliferate extensively in vitro while
maintaining their undifferentiated multi-potent
stage
-Need to optimize differentiation protocols
depending on the source tissue-Biosafety/MSC
senescence/transformation upon long-term cul-
ture-Homing to the damaged tissue is desired-
Lack of a commercial GMP licenced MSC prod-
uct-Optimal route of MSC delivery must be
defined for individual indications-MSC purity
and optimal dose remain to be specified
Vehicles for gene therapy -Easy to transfect/transduce-Opposite to HSCs,
MSCs proliferate extensively in vitro while
maintaining their undifferentiated multi-potent
stage
-Absence of clinical data-Confirmation is still
required about potential transgene silencing
upon differentiation-Risk of insertional 
mutagenesis
Enhance engraftment in HSCT -MSCs are capable of homing to the BM and
survive-MSCs are not rejected due to their low
immunogeneicity-Encouraging preliminary 
pre-clinical/clinical data with low toxicity
-Allo-MSC may mount a T-cell memory
response in non-myeloablated hosts-
Logistic/timing issues in auto-HSCT-Lack of a
commercial GMP licenced MSC product-
Optimal route of MSC delivery must be defined
for individual indications-MSC purity and opti-
mal dose remain to be specified
Diminish GvHD -Low immunogeneicity-Immunotolerance prop-
erties-Encouraging preliminary pre-clinical/clin-
ical data with low toxicity
-Amount, timing and source of MSCs are cru-
cial and must be considered-Multiple but not
single MSC infusions may be required-Lack of
a commercial GMP licenced MSC product-
Optimal route of MSC delivery must be defined
for individual-MSC purity and optimal dose
remain to be specified indications.-Potential
increased risk of relapse.
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[51–53]. First, one may consider the non-immunogenicity of
MSCs due to the lack of expression, before differentiation, of MHC
molecules (class II) on their surface. Of note, despite MHC class
II molecules are commonly absent on the surface of MSCs, MSCs
have been shown to contain intracellular deposits of MHC II
alloantigens detectable at the protein level by Western Blot [54].
Second, MSCs may potentially induce T-cell anergy due to the
lack of ligands for CD28 and other costimulatory molecules on
their plasma membrane leading to a state of immunological igno-
rance. Third, stem cells may differentiate and facilitate the estab-
lishment of chimerism through thymic and extrathymic deletion
of autoreactive T-cell clones or the induction of Treg subsets
(either the conventional CD4CD25 T cells, or other cell sub-
sets producing TGF- and/or IL-10) that down-regulate effectors
T-cell responses.
MSCs and cell replacement strategies
MSCs exhibit great potential for cell replacement strategies. This
potential relies on three key properties: (i) their capacity to differ-
entiate into several cell lineages; (ii) their immune-modulatory
properties and (iii) their ability to secrete soluble factors which
regulate crucial biological functions such as proliferation and dif-
ferentiation over a broad spectrum of target cells. An important
consideration is the fact that their immunomodulatory capacity
facilitates allogeneic cell replacement therapies regardless the
degree of HLA match between donor and recipient.
Initially, MSCs were assessed in vivo in cell replacement strate-
gies by transplanting MSCs directly to the injured sites. Recently,
however, alternative strategies typically involve the generation of
an engineered construct by seeding biocompatible scaffolds with
these MSCs [55]. Moreover, current gene delivery methods offer
the possibility of genetic modification of MSCs within these scaf-
folds to secrete the specific soluble signalling molecules expected
to contribute to a specific tissue repair [56]. The MSCs incorpo-
rated into the construct will require a functional vasculature to
receive the metabolic demands for survival, proliferation and dif-
ferentiation. An alternative strategy for this type of tissue engi-
neering would rely on the development of an in vitro vascularized
scaffold, which is then seeded with MSCs [57].
Alternatively, successful cell replacement therapies might be
achieved by harnessing the important intrinsic biological features
of MSCs, which are capable of homing in vivo to sites of tissue
injury, primarily as a result of local production of inflammatory
mediators during tissue damage. If the MSCs are able to home to
the damaged tissue and engraft there, they could be delivered
intravenously. This strategy would be especially interesting in
those scenarios where the damaged tissue is difficult to access
(i.e. central nervous system) or when there are several systemic
organs implicated (i.e. tumour metastasis) [58, 59]. In fact, this
strategy has been widely used in patients with genetic disorders
where transplantation of allogeneic MSCs resulted in partial
response of the clinical manifestations in patients with Hurler syn-
drome, metachromatic leukodystrophy or osteogenesis imper-
fecta [20, 60].
Among the different tissue candidates to take advantage of
potential MSC-based regeneration, bone is probably at the fore-
front of current cell replacement and tissue repair applications.
This may be, at least in part, due to better understanding of the
cellular and molecular mechanisms implicated in MSC-mediated
osteogenesis. MSCs may differentiate relatively easy in vitro into
osteoblasts by treatment with dexamethasone that stimulates
MSC proliferation and promotes osteogenic lineage differentia-
tion. Other supplements such as ascorbic acid phosphate and 1,
25-dihydroxyvitamin D3 and members of the bone morphogenetic
protein (BMP) family of growth factors are also commonly used
for osteogenic induction from MSCs [61]. As aforementioned, the
use of natural and synthetic biomaterials (mainly porous ceramics
of hydroxyapatite and -tricalcium phosphate) as carriers for 
MSC delivery holds the promise for orthopaedic therapeutic 
applications [55].
In addition to osteogenic differentiation capacity and their
potential in bone regeneration, MSCs might also be used for
restoration of function in individuals suffering from cartilage dam-
age. The in vitro induction of chondrogenesis seems to depend on
coordinated activities of many growth factors as well as cell den-
sity and adhesion. The transforming growth factor- (TGF)
superfamily of proteins and the BMPs are well-established regula-
tory factors in chondrogenesis [62]. Although TGF-1 was initially
used for in vitro induction of chondrogenesis from MSCs, TGF-3
has recently been shown to induce a more rapid and thorough
expression of chondrogenic markers [62]. Interestingly, autolo-
gous MSCs have been used in vivo dispersed in gels of collagen-
type-I or alginate in order to enhance the chondrogenic differenti-
ation for repairing defects on femoral condyles [63, 64]. Despite
the very little information, the potential of MSC differentiation into
other connective tissues, such as tendons and ligaments is cur-
rently being investigated.
Myogenic differentiation of MSCs is currently being applied to
cardiac and skeletal muscle [65, 66]. MSCs have been used in
myocardial infarction, resulting in improved remodelling and
reduction of damage size. MSCs injected in the damaged
myocardium disappear over time and there was no evidence of dif-
ferentiation of injected MSCs into cardiomyocytes. Strikingly,
however, there is a growing body of evidence suggesting that
MSCs stimulate the repair of damaged tissue through endogenous
mechanisms [65]. However, compared to the osteoblastic and
chondrocytic lineages, very little is known about the signalling
pathways and molecular determinants involved in myogenic dif-
ferentiation of MSCs. Consequently, the clinical benefits of MSC-
based cell therapies for damaged cardiac and skeletal muscle are
still in their infancy [66].
Differentiation of MSCs into tissues derived from a germ layer
other than mesoderm has also been reported. Thus, MSCs have
been differentiated into neurons and glia, opening up new avenues
to study tropism toward neuroectoderm tissues and long-term
future cell replacement strategies for neurodegenerative diseases
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[67]. Recent data indicate that delivery of soluble factors directly
into the tissue is likely to be the main mechanism of action [67].
In this regard, early intervention tends to be more effective
because MSCs exert a paracrine influence during active tissue
inflammation and therefore MSC grafts are much less effective
once acute injury becomes chronic. A similar situation seems to
occur when MSCs enhance wound healing. In this scenario, MSCs
enhance migration of macrophages, keratinocytes and endothelial
cells to the damaged tissue, inducing their proliferation and accel-
erating wound closure [68]. Worth mentioning, special attention
should be paid to the differentiation of MSCs to unwanted tissues,
which may also represent a serious concern as recently reported
[69]. These authors reported that the developmental fate of BM-
derived MSCs is not restricted by the surrounding tissue after
myocardial infarction and that the MSC fraction may induce unde-
sired bone formation in the infarcted myocardium. These findings
question the biologic basis and clinical safety of using whole BM
and in particular MSCs to treat non-haematopoietic disorders.
Premature clinical use of MSC-based therapies may put
patients at risk, especially since this research field lacks robust
preclinical data using suitable animal models. Therefore, despite
the promise that MSCs hold in cell replacement strategies, caution
is required. Essential precautions need to be taken and biosafety
issues need to be addressed before designing prospective clinical
trials [70]. Our suggestion would be to invest resources, time and
scientific efforts in gaining fundamental knowledge about the
molecular and cellular mechanisms underlying MSC isolation,
maintenance and in vitro and in vivo proliferation and differentia-
tion before moving from the bench to the bedside [16, 70]. The
main advantages and disadvantages linked to the use of MSCs in
the clinic are summarized in Table 2.
Clinical applications based on MSCs
immune modulatory properties:
overview of ongoing clinical trials
As described above, MSCs are multi-potent non-haematopoietic
progenitor cells capable of differentiating into various mesenchy-
mal lineages, being able to migrate to damaged tissues and favour
tissue repair. Biologically, MSCs release cytokines and growth
factors supporting the differentiation of the HSCs, which is based
on an interaction between MSCs and haematopoietic cells through
signalling pathways such as Notch, Tie2 and the axis CXCR4-
CXCL12 [71–74]. From an immunological point of view, the
inhibition of T-cell responses by MSCs correlates with cyclin D2
inhibition [75] and a p27kip1 up-regulation [76]. Both contact
dependent and independent mechanisms have been involved.
They also block the proliferation and differentiation of B lympho-
cytes, in an extracellular response kinase (ERK) and p38 MAP
kinase pathway-dependent manner [77]. They also reduce the
expression of co-stimulatory molecules and down-regulate IL12
secretion in mature antigen presenting cells [78, 79].
The immune-privileged properties attributed to MSCs make
them a powerful tool that could be used in many inflammatory or
autoimmune diseases. They are currently being explored within
several clinical trials, which are summarized below. Most clinical
trials are currently underway or in a participants’ recruitment
phase. The website www.clinicaltrial.gov displays a registry of fed-
erally and privately supported clinical trials conducted not only in
the United States but also worldwide. As reported in this database,
the clinical trials based on the immune modulatory properties of
MSCs can be divided in five groups:
a) Immune protection against rejection after solid organ or
HSCs transplantation.
Examples are: (i) co-transplantation of MSCs along with
pancreatic islets for type 1 diabetic patients (Fuzhou General
Hospital, China) in order to protect the transplanted islets
from inflammatory damage, thus facilitating islet engraft-
ment and (ii) MSCs transplantation in recipients who have
undergone a kidney transplant in order to suppress immune
rejection and improve donor kidney survival (Fuzhou
General Hospital, China).
b) Treatment of chronic inflammatory diseases. For instance,
MSCs transplantation in decompensate cirrhosis (University
of Tehran, Iran) or chronic allograft nephropathy (Fuzhou
General Hospital, China).
c) Treatment of autoimmune diseases. Immunological proper-
ties of MSCs are being currently harnessed in multiple sclero-
sis clinical trials (University of Cambridge, UK) and in Lupus
Nephritis clinical trials (Organ Transplant Institute, China).
d) Treatment of diseases of unknown aetiology but with a strong
inflammatory response. MSCs are being used in Crohn’s dis-
ease to decrease inflammation (Osiris Therapeutics) and in
the treatment of moderate to severe Chronic Obstructive
Pulmonary Disease (Osiris Therapeutics).
e) Treatment of GVHD after an allogeneic HSC transplantation
(HSCT). Allogeneic HSC transplant is a well-established
treatment for several haematopoietic and non-haematopoi-
etic diseases. Recipients receiving an allogeneic HSCT are
immunosuppressed in order to prevent rejection of the
transfused HSCs. GVHD is induced by T cells either trans-
planted or generated from infused donor HSCs, which react
with donor tissue. Because of their immunoregulatory
capacity, ex vivo expanded MSCs are being used in clinical
trials to treat severe GVHD [80]. To date, GVHD is probably
the more susceptible disease prone to be treated with MSCs.
In fact, many multi-centre randomized trials have been
started. Preliminary results about the use of MSCs in GVHD
are discussed below in detail.
MSC in the HSCT setting
Allogeneic HSCT is a potentially curative treatment option for many
patients diagnosed with haematologic malignancies. Its efficacy is
based both on the high doses of chemotherapy and radiotherapy
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administered prior to transplantation and on the immune effect of
T lymphocytes from the graft which may recognize and exert a
cytotoxic effect against tumour cells from the host inducing a graft-
versus-leukaemia (GVL) effect. An important clinical observation
supporting the proof of principle of this anti-tumour effect is the
fact that patients who relapse after allogeneic transplantation may
reach complete remission after donor lymphocyte infusions [81].
Unfortunately, allogeneic T cells present in the graft also recognize
normal host tissues, causing severe tissue damage in target organs
such as skin, liver and gut, being the underlying mechanism for the
development of GVHD [82, 83], which remains one of the most
severe complications after allogeneic transplantation. The fre-
quency of GVHD is around 30% and 80% among recipients of
HLA-matched sibling or unrelated donor transplants, respectively.
Steroids are still the first-line treatment for established GVHD with
a response rate of 30–50%. Unfortunately, the outcome for
patients with severe, steroid-resistant acute GVHD is very poor, and
the overall survival is low [82, 83].
Based on their immune modulatory properties, MSCs have
been used as a promising approach for the treatment of GVHD
[84]. Le Blanc K et al. [13] transplanted haploidentical MSCs to a
patient with severe treatment-resistant grade IV acute GVHD of the
gut and liver. The clinical response was striking with normalization
of stool and bilirubin on two separated occasions. Subsequently,
the same authors reported their experience on eight patients with
steroid refractory grades III–IV acute GVHD and one patient with
extensive chronic GVHD treated with MSCs [85]. Strikingly, acute
GVHD disappeared completely in 75% of patients [85]. These
studies have been further extended in Europe with 55 patients
enrolled [86]. These patients have been treated for steroid-resist-
ant acute GVHD who had previously failed to first line treatment 
(n  55), second line (n  33), third line (n  14) or fourth or more
line treatment (n  6). The median dose of bone-marrow derived
MSCs was 1.4  106 cells per kg bodyweight. Twenty-seven
patients received one dose, 22 patients received two doses, and 6
patients received three to five doses of MSCs obtained from HLA-
identical sibling donors (n  5), haploidentical donors (n  18)
or third-party HLA-mismatched donors (n  69). The overall
response rate was 71% with 30 patients achieving a complete
response and 9 patients a significant GVHD clinical improvement.
Median time from first MSC infusion to clinical response was 18
days [86]. Interestingly, the HLA match of the allogeneic MSCs
and the donor had no effect on response rate. No patients had side
effects during or immediately after infusions of MSCs. Complete
responders had lower transplantation-related mortality 1 year after
infusion than did patients with partial or no response (37% versus
72%) and higher overall survival 2 years after HSCT (53% versus
16%) [16]. MSCs may be obtained from several sources in addi-
tion to BM [87]. Subsequently, in a series of 6 patients with
steroid-resistant acute GVHD treated with adipose-tissue-derived
MSCs complete response was documented in 83% of patients.
Median dose of infused MSCs was 1  106/kg and no side effects
were observed after the infusion [88]. Therefore, although the
experience is limited, MSCs seem a promising alternative
approach to treat severe steroid-resistant acute GVHD [86–89].
Because MSCs are immunosuppressive and may alleviate
GVHD, it is unknown whether MSCs will increase the risk of
leukaemic relapse by abrogating the GVL effect. In a prospective
randomized trial, HLA-identical sibling-matched HSCs were trans-
planted alone (non-MSC group, n  15) or co-transplanted with
MSCs (MSC group, n  10) in patients suffering from haematopoi-
etic malignancies. The median number of MSCs infused was 3.4 
105/kg. MSC infusions were well tolerated and the median time to
neutrophil engraftment was 16 days for MSC group and 15 days
for non-MSC group. The median time to platelet engraftment was
30 and 27 days, respectively. Grades II–IV acute GVHD was
observed in 10% and 53.3% of patients from the MSC and non-
MSC groups, respectively. Similarly, chronic GVHD was found in
14% and 29% of patients from the non-MSC and MSC groups,
respectively. However, the proportion of patients who relapsed was
60% and 20%, and the 3-year disease-free survival was 30% and
67% in the MSC and non-MSC groups, respectively [89].
According to this study, co-transplantation of MSCs and HSCs may
have prevented GVHD, but the relapse rate was significantly higher
in the group where MSCs were co-infused along with HSCs. These
results clearly indicate that MSCs should be handled with extreme
caution before a large-scale prospective clinical trial is undertaken.
However, as pointed out by Vianello et al. [90], there is an aspect
that does not entirely fit with the data, that is, the absence of differ-
ences in the number of infectious events in the group of patients
treated with MSCs, since a non-selective immunosuppression
would have equally affected patient’s antiviral immunity. Therefore,
alternative mechanisms may be involved in the clinical conse-
quences of MSC transplantation and, in this regard recent evidence
supports the capability of the haematopoietic milieu to be the sole
causative mechanism of cancer development [73, 91]. Accordingly,
further investigations on MSC homing may help to clarify the
mechanisms responsible for the clinical outcome. In this regard,
46 patients underwent co-transplantation of in vitro-expanded
MSCs plus HSCs from their HLA-identical sibling donors [92].
Moderate to severe acute GVHD was observed in 28% of patients.
Chronic GVHD was observed in 61% of patients and 2-year pro-
gression-free survival was 53%. No MSC-associated toxicities
were reported. Similar to the percentage reported in previous
series, stromal cell chimerism was demonstrated in 2 of 18 exam-
ined patients after transplantation [93]. These studies provide
insights into the difficulties in detecting MSCs after infusion, even
in immunocompromised patients who have undergone an HSCT.
As far as the use of MSC in the GVHD prophylaxis or treatment is
concerned, there are several clinically relevant questions that need
to be addressed. What are the optimal timing, cell dose and addi-
tional immunosuppressive therapy to be used? Might the use of
MSCs be better indicated for a specific disease or specific cohort
of patients? Double-blind, randomized studies using MSC versus
placebo have started in Europe and in the USA in patients with
steroid-resistant acute GVHD.
In addition to their immunosuppressive effect, MSCs enhance
haematopoietic engraftment and several clinical trials have been
devoted to confirm this potential. In the previously mentioned
study from Lazarus et al. [92], median days to reach 500/mm3
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granulocytes and 20,000 platelets/mm3 were 14 and 20 days
after transplantation, respectively. In this regard, haploidentical
HSCT is associated with an increased risk of graft failure. In order
to enhance haematopoietic recovery, MSCs were co-transplanted
in 14 children undergoing transplantation of CD34 HSCs from a
haploidentical donor. While a 15% haematopoietic graft failure
rate was observed in 47 historical controls, all patients given
MSCs showed sustained haematopoietic engraftment, without any
adverse reaction. Furthermore, children given MSCs experienced
fewer infections than controls [94]. These data suggest that MSCs
reduce the risk of graft failure in patients undergoing a haploiden-
tical HSCT. Finally, in the autologous HSCT setting, 28 patients
diagnosed with breast cancer received autologous MSCs in addi-
tion to HSC. Clonogenic MSCs were detected in peripheral blood
up to 1 hr after infusion in 62% of patients. Median time to achieve
500 granulocytes/mm3 and 20,000 platelets/mm3 was 8 and
8.5 days, respectively, suggesting that infusion of MSCs after
myeloablative conditioning seems to have a positive impact on
haematopoiesis [21].
Clinical use of MSCs in regenerative medicine 
to facilitate tissue repair
Since MSCs are able to migrate to damaged tissues, this property
can be exploited in regenerative medicine and tissue repair. Ten
patients undergoing allogeneic HSCT were administered MSCs due
to tissue toxicity. Five patients with severe haemorrhagic cystitis
cleared after MSC infusion. Two patients were treated for pneumo-
mediastinum, which also disappeared after MSC infusion and a
patient with steroid-resistant GVHD of the gut experienced perfo-
rated diverticulitis and peritonitis that was also reversed after infu-
sion of MSCs [95]. These preliminary data suggest that MSCs may
also play a role in repairing HSCT-associated severe tissue toxicity.
Besides HSCT, clinical trials are underway to evaluate the
potential use of MSCs in repairing damaged or lost tissue in
osteoarthritis, steroid-induced avascular osteonecrosis, anal fis-
tula and intervertebral discs [96–98]. Although these pre-clinical
and clinical trials are still very preliminary, the results are promis-
ing and therefore efforts in this cell therapy field should be contin-
ued [96–98]. In conclusion, the use of MSCs in cellular therapy is
already being explored in several settings, especially in HSCT with
three goals: (i) to enhance HSC engraftment, (ii) to treat/alleviate
GVHD and (iii) to promote tissue repair.
MSCs as a model to study cell 
transformation and disease
In agreement with the cancer stem cell theory [99], MSCs might
constitute a target cell for some transforming mutations and chro-
mosomal abnormalities, which may arise in an MSC or mesoder-
mal precursor, giving rise to non-haematopoietic mesenchymal
tumours such as sarcomas. For instance, it has been shown that
the expression of FUS-DDIT3, a fusion oncoprotein previously
involved in the development of myxoid liposarcoma [100], in
mouse is capable of transforming MSCs recapitulating in vivo the
development of such a tumour [101]. Likewise, Ewing’s sarcoma
has been reproduced in vivo by expression of EWS-FLI-1 in MSCs
[102, 103]. In another work, the expression of EWS-FLI fusion
protein in human MSCs induced a pattern of gene expression sim-
ilar to that observed in human Ewing’s sarcoma [104]. Different
types of sarcomas can also be generated from transformed MSCs.
This is the case of the malignant fibrous histiocytoma derived
from MSCs inactivated for Wnt signalling [105]. Recently, a clas-
sification of liposarcomas based on the differentiation state of the
MSCs that give rise to the tumours has been suggested [106].
Other groups have reported in vitro MSC transformation after
ectopic expression of the telomerase hTERT [107] or the onco-
genic H-ras [108] genes. It was also described that BM-derived
cells (most likely MSCs) chemically transformed using 3methy-
cholanthrene could form many types of tumours [109]. Together,
these data further link cancer to development and support the idea
that MSCs could play a relevant role and become an instrumental
tool in studies about the aetiology and pathogenesis of sarcomas.
One should consider, though, that the role of MSCs in
tumourogenesis could be an indirect phenomenon. MSCs are fre-
quently recruited to the site of tissue injury and sometimes, in the
appropriate and permissive environment and under stress condi-
tions, this could also represent a potential source of malignancy.
It was described that BM-derived MSCs recruited after infection
with H. pilori could be the origin of gastric cancers [110].
Likewise, the presence of MSCs in the tumour stroma could facil-
itate breast cancer metastasis [111] or the growth of syngeneic
tumours [112, 113] due, in part, to the high migration and mobil-
ity associated to a mesenchymal/fibroblastoid phenotype.
Moreover, BM-MSCs seem to create in many cases an optimal
microenvironment for the development of several tumours such
as multiple myeloma [91, 114] or acute lymphoblastic leukaemia
[115]. Activation of anti-apoptotic pathways seems to play a cen-
tral role in this regard since BM-derived MSC are resistant to
chemotherapy-induced apoptosis [116] and also contribute to
generate drug resistance in tumour cells [115, 117].
It is worth mentioning that in addition to these MSC-based cell
transformation models, human MSCs may transform sponta-
neously in vitro at higher frequency than other primary human
stem cells. Human adipose tissue-derived MSCs have been shown
to undergo spontaneous transformation after long-term in vitro
culture [16]. These transformed MSCs can form carcinomas in
mice through an unusual mesenchymal to epithelial transition
[118]. It was also reported the outgrowth of a transformed popu-
lation derived from cultured human BM derived-MSC [119]. The
same phenomenon was also observed in murine BM-derived MSC
[15, 120, 121]. Nevertheless, some controversy has recently
arisen in the field, since Bernardo et al. [14] reported a lack of
MSC transformation after extensive in vitro culture. Similarly,
another study showed that despite MSCs from both human and
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rhesus macaques show cell cycle alterations after extended 
in vitro culture, only the monkey MSCs display chromosomal
alterations and both types of MSCs fail to generate tumours 
in vivo [122]. The phenomenon of spontaneous transformation of
MSCs has been very recently described for the first time and due
to the controversy further investigation efforts are still required to
ascertain whether or not MSC transformation is inherent to MSC-
specific intrinsic properties or is an indirect effect of underlying
confounding mechanisms or specific pathological conditions.
In contrast to the susceptibility of MSCs to transformation,
there are studies claiming a potential role of these cells in anti-
cancer therapy. Human MSCs can home to tumour sites and
inhibit the growth of neoplastic cells as has been shown in animal
models of glioma [123], Kaposi’s sarcoma [124] or hepatoma
[125, 126]. Due to the ability of MSCs to migrate and seed
tumours, they have also been used as vehicles to deliver oncolytic
viruses into tumours and metastasis [127, 128, and García-Castro
J et al. (submitted)]. MSCs over-expressing the apoptotic inducer
TRAIL [129] or IFN- [58] were able to inhibit tumour growth in a
lung cancer and pulmonary metastases models, respectively, sup-
porting the potential of MSCs as anti-cancer therapeutic option to
inhibit the growth of cancer cells. All of these studies reveal the
importance of having in place appropriate biosafety, standardiza-
tion and quality controls before translating MSC application into
the clinic. The genetic stability of MSCs in the ex vivo culture
process represents a key issue and the absence of transformation
should be documented before infusion of MSCs into patients.
Despite the above evidence of MSC transformation, little is still
known about its mechanistic basis. MSC transformation has often
been linked to the accumulation of chromosome instability [15,
16, 119, 121]. This observation, together with the high resistance
of MSCs to apoptosis [116], supports the relevance of an accurate
cell cycle control in MSCs. In fact, alterations in cell cycle regula-
tors such as p16INK4A [16, 108] or p53 [16, 120], have been
detected in transformed MSCs. Furthermore, over-expression of
c-myc [15, 16] and the acquisition of telomerase activity [16, 107,
119] are other common events associated to the transformation
process. Characterization of small but biologically relevant molec-
ular changes using high-resolution technologies including
microarrays or spectral kariotyping displayed alterations in the
expression of genes involved in cell cycle regulation, protein-ubiq-
uitination and apoptosis after extended culture in vitro [16, 122].
A two sequential step model of MSC transformation has been pro-
posed [130]. In the first step, cells would bypass senescence by
up-regulation of c-myc and repression of p16INK4A. In a second
step, cells would bypass senescence by gaining telomerase activ-
ity, Ink4a/Arf locus deletion and Rb hyperphosphorilation. These
changes would be accompanied with alterations in other cell cycle
regulators (CDK-1, 2 and 6) and DNA damage repair proteins
(Rad51, XRCC4, etc.) [130].
Finally, the role of Wnt signalling, a key developmental sig-
nalling pathway, in MSC transformation requires some discussion.
Wnt seems important in tumourogenesis induced by MSCs. The
canonical Wnt/-catenin signalling pathway plays a central role in
modulating the balance between self-renewal and differentiation in
stem cells [131]. In addition, Wnt signalling also regulates the
invasion capacity and the proliferation of human MSC [132, 133].
Wnt signalling is also involved in the epithelial-to-mesenchymal
transition. While these properties exerted by the Wnt pathway may
be useful in tissue regeneration, an inadequate activation of this
pathway may deregulate the balance between proliferation, differ-
entiation and apoptosis and, most importantly the epithelial-to-
mesenchymal transition seen in many carcinomas and strongly
related with malignant behaviour [134], leading therefore to a
malignant transformation [91, 105, 134].
In summary, in line with the well-established link between
development, stem cells and cancer, MSCs are being exploited as
a target cell for the origin of mesenchymal tumours, especially
sarcomas. In addition, whether MSCs and stroma cells form part
of the neoplastic clone and their potential contribution to the
tumour microenvironment is under active investigation.
Nevertheless, very little is still known about the mechanisms of
MSC transformation and more research efforts are required to find
target-specific therapies against these mesenchymal tumours.
Further studies on MSC spontaneous transformation will also be
of great value to ensure the quality and biosafety of MSCs in clin-
ical trials.
Concluding remarks
MSCs exist in BM and other tissues and are one of the most prom-
ising adult stem cell types because of their availability and the rel-
atively simple requirements for in vitro expansion. These cells
contribute to the homeostasis of mesenchymal tissues and sup-
port the growth and differentiation of HSCs. A striking feature of
the MSCs is their low inherent immunogenicity. Instead, MSCs
appear to be immunosuppressive in vitro. Their multi-lineage dif-
ferentiation potential coupled to their immuno-privileged proper-
ties is being exploited for both autologous and allogeneic cell ther-
apies, tissue engineering and regenerative medicine. Additionally,
the rapid evolution of experimental data has acknowledged the
critical relevance of MSCs as the target cell for either spontaneous
or induced cell transformation representing a potential platform
for modelling non-haematological mesenchymal cancers such as
sarcomas. In this review, we have briefly outlined the current sta-
tus of MSCs, focusing on their biological characteristics and
potential for clinical applications.
Stem cell therapy is rapidly developing and has generated
excitement and promise as well as confusion and at times contra-
dictory results in the lay and scientific literature. Despite the great
promise held by MSCs and although several clinical trials are
underway for a variety of malignant disorders, HSCT or regenera-
tion of damaged tissues, it must be recognized that MSCs are
poorly defined by a combination of physical, phenotypical and
functional properties. As MSCs could be derived from different tis-
sues as starting material, by diverse isolation protocols, cultured and
expanded in different media and conditions, the MSC preparations
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from different laboratories are highly heterogeneous. All of these
variables might have implications on (i) the selection of cell types
and the composition of heterogeneous subpopulations, (ii) they
can selectively favour expansion of different cell populations with
totally different potentials and (iii) they might alter the long-term
fate of adult stem cells upon in vitro culture. The recent contro-
versy on the multi-lineage differentiation potentials of some spe-
cific MSC preparations might be attributed to this lack of common
standards. In addition, the most appropriate source of MSCs,
method of isolation and expansion, dose to be infused, timing and
route of delivery, and adverse biosafety effects like the potential of
MSCs to undergo spontaneous transformation still need to be
determined. More precise genetic stability studies, molecular and
cellular markers to define subsets of MSCs and the standardiza-
tion of the protocols for expansion of MSC are urgently needed.
Also, a recent study [135] suggest that MSCs may not be as
immunoprivileged as initially thought and therefore further ‘in
depth’ insights about the immunological mechanisms underlying
the immunosuppressive effects of MSCs are still in high demand.
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